Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...
Drug stock Moderna (MRNA) is pulling back to a historically bullish trendline and has plenty of contrarian signals flashing ...
Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...
Aug 4 (Reuters) - Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against ...
Operator: Good day, and thank you for standing by. Welcome to the Moderna Second Quarter 2026 Conference Call. Please be ...
Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results